Unity Biotechnology, Inc.UBXNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank25
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P25
Within normal range
vs 5Y Ago
-1.8x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2024-37.47%
2023-43.57%
2022-4.00%
2021-42.96%
2020-5.14%
201920.46%
201857.62%
2017172.66%
20160.00%